Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where H Monsanto is active.

Publication


Featured researches published by H Monsanto.


International Journal of Infectious Diseases | 2015

Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia

Kosuke Kawai; E. Rampakakis; Tsen-Fang Tsai; Hee Jin Cheong; Jittima Dhitavat; Alejandro Ortiz Covarrubias; Lin Yang; Miguel Cashat-Cruz; H Monsanto; Kelly D. Johnson; John S. Sampalis; Camilo J. Acosta

OBJECTIVES The most common complication of herpes zoster (HZ) is postherpetic neuralgia (PHN), a persistent pain that can substantially affect quality of life (QoL). This analysis aimed to evaluate predictors of PHN in HZ patients. METHODS A pooled analysis of prospective cohort studies of HZ patients aged ≥ 50 years from North America (Canada), Latin America (Brazil, Mexico, and Argentina), and Asia (Taiwan, South Korea, and Thailand) was performed. Patients within 14 days of rash onset were included. The incidence of PHN was defined as a worst pain score of ≥ 3, persisting/appearing at >90 days after rash onset. Socio-demographics, HZ disease characteristics, treatment, pain-related interference with activities of daily living, and health-related QoL were assessed. RESULTS Of 702 patients with HZ, 148 (21.1%) developed PHN. Similar risks of PHN were observed across geographic regions. On multivariate analysis, older age, greater severity of pain at rash onset, employment status, walking problems at enrollment, and pain interference affecting social relationships were significantly associated with the development of PHN. CONCLUSIONS In addition to older age and severe acute pain, this study suggests that impaired physical and social functioning from acute zoster pain may play a role in the development of PHN in this prospective cohort study of HZ patients from North and Latin America and Asia.


Journal of Medical Economics | 2018

Economic burden of varicella in children 1–12 years of age in Argentina, 2009–2014

Norberto Giglio; H Monsanto; E. Rampakakis; H. Keri Yang; Barbara J. Kuter; Lj Wolfson

Abstract Background: In Argentina, varicella vaccination was included in the national schedule for mandatory immunizations in 2015. The vaccine has been shown to substantially reduce the morbidity and mortality associated with the virus. The purpose of this study was to evaluate the clinical and economic burden associated with varicella in Argentina prior to vaccine introduction. Methods: This was a multi-center, retrospective chart review study among patients aged 1–12 years with a primary varicella diagnosis in 2009–2014 in Argentina. Healthcare resource utilization (HCRU) associated with varicella and its complications, unit costs, and work loss were used to estimate direct and indirect costs. All costs are presented in 2015 United States dollars (USD). Results: One hundred and fifty children with varicella were included (75 outpatients, 75 inpatients), with a mean age of 3.8 (SD = 2.4) and 2.9 (SD = 2.2) years, respectively. One or more complications were experienced by 28.0% of outpatients and 98.7% of inpatients, the most common being skin and soft tissue infections, pneumonia, sepsis, cerebellitis, and febrile seizure. HCRU estimates included use of over-the-counter (OTC) medications (58.7% outpatients, 94.7% inpatients), prescription medications (26.7% outpatients, 77.3% inpatients), tests/procedures (13.3% outpatients, 70.7% inpatients), and consultation with allied health professionals (1.3% outpatients, 32.0% inpatients). The average duration of hospital stay was 4.9 (95% CI = 4.2–5.7) days, and the average duration of ICU stay was 4.8 (95% CI = 1.6–14.1) days. The total combined direct and indirect cost per varicella case was 2947.7 USD (inpatients) and 322.7 USD (outpatients). The overall annual cost of varicella in Argentina for children aged ≤14 years in 2015 was estimated at 40,054,378.0 USD. Conclusion: The clinical burden of varicella in Argentina was associated with utilization of significant amounts of healthcare resources, resulting in substantial economic costs. These costs should be reduced with the recent implementation of routine vaccination of children.


Clinics | 2018

Measuring herpes zoster disease burden in São Paulo, Brazil: a clinico-epidemiological single-center study

João Toniolo-Neto; Eliofotisti Psaradellis; Angela Karellis; E. Rampakakis; Talita Y. Rockett; John S. Sampalis; Kelly D. Johnson; H Monsanto; Camilo J. Acosta

OBJECTIVES: Herpes zoster is characterized by acute neuritis and post-herpetic neuralgia. Currently, data concerning the zoster-associated impact on quality of life and healthcare resource utilization in Brazil are scarce. This study measured the zoster-associated burden in a Brazilian population. METHODS: This was a prospective, observational, single-cohort study conducted in a primary hospital’s emergency room in São Paulo, Brazil. Patients enrolled at various timepoints during a zoster episode were followed over 180 days. The Zoster Brief Pain Inventory and the Initial Zoster Impact Questionnaire assessed zoster-associated pain. The EuroQoL assessed the impact of herpes zoster and/or zoster-associated pain on quality of life. Healthcare resource utilization was assessed by patient-reported questionnaires. RESULTS: One-hundred forty-six zoster patients were enrolled [mean (SD) age of 69.9 (10.9) years]. Mean (SD) worst pain scores decreased from 5.3 (3.5) at baseline to 1.9 (3.0) 180 days following rash onset. Mean (SD) EuroQoL scores significantly decreased from 0.9 (0.2) before rash appearance to 0.7 (0.2) after rash onset (p<0.001), followed by gradual improvements in quality of life over 180 days, with pre-herpes zoster quality of life achieved at the end of the observation period. The majority of patients purchased prescription medications (89.7%) and required doctor’s office visits (65.8%) for zoster episodes. CONCLUSIONS: Herpes zoster is associated with a significant disease burden, including zoster-associated pain, impaired quality of life and increased healthcare resource utilization in Brazil. These results support the implementation of early intervention and prevention programs such as vaccinations to reduce the herpes zoster-associated disease burden in Brazil.


Health and Quality of Life Outcomes | 2017

Association between work time loss and quality of life in patients with Herpes Zoster: a pooled analysis of the MASTER studies

E. Rampakakis; Melissa Stutz; Kosuke Kawai; Tsen-Fang Tsai; Hee Jin Cheong; Jittima Dhitavat; Alejandro Ortiz-Covarrubias; Miguel Cashat-Cruz; H Monsanto; Kelly D. Johnson; John S. Sampalis; Camilo J. Acosta

BackgroundHerpes zoster (HZ) has a significant negative effect on the productive work life of individuals, and has been shown to be responsible for cases of absenteeism, presenteeism and decreased work effectiveness. The aim of this study was to evaluate health utility scores and associated predictors in an actively employed population of Herpes Zoster (HZ) patients with and without work time loss (WTL).MethodsThis was a pooled analysis of the prospective, observational MASTER cohort studies, conducted in 8 countries across North America, Latin America and Asia. A total of 428 HZ patients engaged in full or part time work were included. WTL, defined as missing ≥ 1 partial or full work day, and work effectiveness, reported on a scale of 0–100%, were evaluated with the Work and Productivity Questionnaire (WPQ). The Pearson product–moment correlation was used to assess the correlation between work effectiveness and HRQoL. Mixed models with repeated measures assessed the relationship between HZ-related WTL over a 6-month follow-up period, and HRQoL, as evaluated by the EQ-5D. Additional predictors of HRQoL were also identified.ResultsOverall, 57.7% of respondents reported WTL. Mean (SD) percent work effectiveness of patients in the WTL group was significantly lower compared to non-WTL (NWTL) patients at baseline [50.3 (31.6) vs. 71.4 (27.8); p < 0.001]. Patients in the WTL group also reported lower health utility scores at baseline and overall than their NWTL counterparts, with WTL identified as an independent negative predictor of both the EQ-5D summary scores and the EQ-5D VAS (p < 0.001). Decrease in work effectiveness was negatively associated with HRQoL overall (p < 0.001). Predictors of lower HRQoL were worst Zoster Brief Pain Inventory (ZBPI) pain score, the presence of HZ complications and country income (predictor of EQ-5D VAS only).ConclusionsHZ adversely impacts the work and productive life of actively employed individuals. In turn, HZ-related reductions in work effectiveness and work time are associated with a negative effect on HRQoL.


Value in Health | 2018

The Economic Burden of Varicella in Mexico

M Vazquez; C Perezbolde; H Monsanto; E Rampakakis; A Altland; Lj Wolfson; V Pastor


Value in Health | 2017

An Updated Review Of The Health & Economic Burden Of Varicella In Latin America And The Caribbean

M Cashat-Cruz; Ci Parellada; H Monsanto; G Mangat; S Kamra; Tj Weiss; Lj Wolfson


Value in Health | 2017

Economic Burden Of Herpes Zoster (“CULEBRILLA”) In Latin America

E. Rampakakis; C Pollock; C Vujacich; João Toniolo Neto; A Covarrubias; H Monsanto; Kelly D. Johnson


Value in Health | 2017

The Cost-Effectiveness of Varicella Vaccination In Peru

M Blas; R Gutierrez; V Petrozzi; H Monsanto; P Best; M. Pillsbury; Tj Weiss; Andrew Pavelyev; Lj Wolfson


Value in Health | 2017

The Economic Burden of Varicella in Peru

Me Castillo; R Gutierrez; H Monsanto; E Rampakakis; A Altland; Lj Wolfson


Value in Health | 2017

The Implications of Vaccine Characteristics and Private-Sector Vaccination on Varicella; A Model-Based Analysis for Mexico

H Monsanto; M Cashat-Cruz; J Kyle; C Perezbolde; M. Pillsbury; Tj Weiss; Lj Wolfson

Collaboration


Dive into the H Monsanto's collaboration.

Researchain Logo
Decentralizing Knowledge